In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014)

136Citations
Citations of this article
81Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae. Most meropenem-nonsusceptible metallo-β-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Isolates that carried KPC or OXA-48-like β-lactamases, both alone and in combination with extended-spectrum β-lactamases (ESBLs) and/or AmpC β-lactamases, were 98.7% and 98.5% susceptible to ceftazidime-avibactam, respectively. Meropenem-nonsusceptible, carbapenemase-negative isolates demonstrated 94.7% susceptibility to ceftazidimeavibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-β-lactamases.

Cite

CITATION STYLE

APA

De Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016). In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrobial Agents and Chemotherapy, 60(5), 3163–3169. https://doi.org/10.1128/AAC.03042-15

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free